粪便潜血损失可准确预测未来结直肠癌检出:一项预后模型研究
该预后模型研究基于荷兰2014—2018年每两年一次粪便免疫化学检测(FIT)筛查项目,纳入265881名完成三轮FIT且前两轮阴性(F-Hb<47 µg Hb/g粪便)的参与者,评估年龄、性别及前两轮F-Hb对第三轮检出进展期肿瘤(AN)和结直肠癌(CRC)的预测价值。结果显示前两轮F-Hb是最强预测因子,最高F-Hb类别调整OR达9.4(95%CI 7.5至11.7),模型对AN和CRC的C统计量分别为0.78和0.73,外部验证中保持相似区分度。作者认为可基于此信息考虑风险分层。
要点
- 前两轮F-Hb浓度是未来检出AN或CRC的最强预测因子。
- 模型预测AN风险范围0.4%至36.7%,CRC风险范围0.0%至5.5%。
- 作者认为可基于年龄、性别及既往F-Hb浓度考虑风险分层。
核心结论
- 基于年龄、性别尤其是既往F-Hb浓度,可准确识别未来AN或CRC风险较低与较高的参与者。
- 作者认为应基于此信息考虑风险分层。
研究设计与样本
- 预后模型研究,数据来自荷兰2014—2018年每两年一次FIT筛查项目。
- 纳入265881名完成三轮FIT且第1、2轮阴性(F-Hb<47 µg Hb/g粪便)的参与者。
- FIT阳性(F-Hb≥47 µg Hb/g粪便)者接受结肠镜随访。
- 以年龄、性别、第1、2轮F-Hb及其类别/组合/非线性转换为预测因子,评估第3轮检出AN和CRC的预后模型。
主要发现
- 8806名(3.3%)FIT结果阳性,3254名(1.2%)检出AN,557名(0.2%)检出癌症。
- 第1、2轮F-Hb是最强结局预测因子,最高F-Hb类别调整OR达9.4(95%CI 7.5至11.7)。
- 风险预测与大多数参与者观察风险匹配(校准截距-0.008至-0.099;斜率0.982至0.998)。
- 模型区分有无AN或CRC的C统计量分别为0.78(95%CI 0.77至0.79)和0.73(95%CI 0.71至0.75)。
- 预测AN风险范围0.4%至36.7%,CRC风险范围0.0%至5.5%。
临床怎么用
- 作者认为可基于年龄、性别及既往F-Hb浓度考虑风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the prognostic potential of repeated faecal haemoglobin (F-Hb) concentration measurements in faecal immunochemical test (FIT)-based screening for colorectal cancer (CRC). DESIGN: Prognostic model. SETTING: Dutch biennial FIT-based screening programme during 2014-2018. PARTICIPANTS: 265 881 participants completing three rounds of FIT, with negative test results (F-Hb <47 µg Hb/g faeces) in rounds 1 and 2. INTERVENTIONS: Colonoscopy follow-up in participants with a positive FIT (F-Hb ≥47 µg Hb/g faeces). MAIN OUTCOMES: We evaluated prognostic models for detecting advanced neoplasia (AN) and CRC in round 3, with as predictors, participant age, sex, F-Hb in rounds 1 and 2, and categories/combinations/non-linear transformations of F-Hb. Primary evaluation criteria included: risk prediction accuracy (calibration), discrimination of participants with versus without AN or CRC (optimism-adjusted C-statistics, range 0.5-1.0), the degree of risk stratification and C-statistics in external validation. RESULTS: Among study participants, 8806 (3.3%) had a positive FIT result, 3254 (1.2%) had AN detected and 557 (0.2%) had cancer. F-Hb concentrations in rounds 1 and 2 were the strongest outcome predictors, with adjusted ORs of up to 9.4 (95% CI 7.5 to 11.7) for the highest F-Hb category. Risk predictions matched the observed risk for most participants (calibration intercept -0.008 to -0.099; slope 0.982-0.998), and discriminated participants with versus without AN or CRC with C-statistics of 0.78 (95% CI 0.77 to 0.79) and 0.73 (95% CI 0.71 to 0.75), respectively. The predicted risk ranged from 0.4% to 36.7% for AN and from 0.0% to 5.5% for CRC across participants. In external validation, the model retained similar discrimination accuracy for AN (C-statistic 0.77, 95% CI 0.66 to 0.87) and CRC (C-statistic 0.78, 95% CI 0.66 to 0.91). CONCLUSION: Participants at lower versus higher risk of future AN or CRC can be accurately identified based on their age, sex and particularly, prior F-Hb concentrations. Risk stratification should be considered based on this information.
引用
- Meester RGS, van de Schootbrugge-Vandermeer HJ, Breekveldt ECH, et al. Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. Gut. 2022. PMID: 35537811. doi:10.1136/gutjnl-2022-327188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。